Millennium kept at neutral by Merrill

Millennium Pharmaceuticals, Inc. was maintained at a neutral rating by Merrill Lynch analyst Thomas McGahren. The company reported a fourth-quarter 2005 earnings per share $0.07, in line with Merrill's estimate and consensus, as Velcade sales of $192 million had been pre-announced. Company guidance for 2006 remains unchanged. It expects U.S. Velcade sales of $225 to 250 million. Shares of the Cambridge, Mass., pharmaceutical company were up 7 cents, or 0.69%, at $10.28 on volume of 3,372,356 shares versus the three-month running average of 4,306,080 shares. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.